For manufacturers of vitro diagnostic medical devices, regulatory compliance does not begin at submission and end at approval. It starts with a structured performance evaluation process and continues through structured post market surveillance pms activities. BaxMed provide IVD performance evaluation support and IVD post market surveillance support to help you demonstrate conformity with safety and performance requirements and maintain compliance under the vitro diagnostic regulation IVDr and other global frameworks.

Our role is to work alongside your team, building a clear regulatory pathway based on intended purpose, device classification, and target markets. We support both early stage strategy and ongoing lifecycle obligations, with a focus on clarity, traceability, and alignment with the medical devices regulation and IVDR expectations.

IVD performance evaluation support

Under the vitro diagnostic regulation IVDr, every IVD medical device must have a documented and justified performance evaluation. This is not a single study but a structured process that brings together scientific validity analytical performance and clinical performance into a coherent body of evidence.

At BaxMed, IVD performance evaluation support begins by defining the intended purpose of the vitro diagnostic IVD. The intended purpose drives the performance evaluation process, including the type of analytical performance studies and clinical performance studies required. We work with you to confirm claims, specimen types, target populations, and settings of use. Clear definitions at this stage reduce rework and support smoother interaction with your notified body.

We then help structure the performance evaluation plan and associated protocols. Analytical performance studies typically assess analytical sensitivity, specificity, precision, reproducibility, and limits of detection. Where analytical sensitivity is a key claim, we ensure study design, acceptance criteria, and statistical methods are aligned with regulatory expectations. For higher risk IVD devices, clinical performance evaluates how the test performs in the intended population and use environment. We review data sources, including clinical performance studies and literature, to confirm relevance and traceability.

The outcome of this work is a robust performance evaluation report. We support drafting, gap analysis, and remediation of the performance evaluation report to ensure it clearly links scientific validity, analytical performance, and clinical performance to the claimed intended purpose. We check internal consistency between the technical documentation, labelling, risk management file, and performance claims. This alignment is central to demonstrating conformity with safety and performance requirements.

Where data gaps are identified, we help you plan additional performance evaluation studies. This may include protocol development for analytical performance studies, oversight of clinical performance studies, or justification of the use of real world data where appropriate. We aim to position your submission so that your notified body review is based on a coherent, well referenced data package rather than fragmented evidence.

Throughout the process, we maintain focus on the benefit risk ratio. The performance evaluation is not only about demonstrating test accuracy. It must show that the benefits of using the vitro diagnostic medical devices outweigh residual risks when used as intended. We support structured benefit risk analysis and ensure that conclusions in the performance evaluation report are supported by data and clearly documented.

IVD post market surveillance support

Approval under the vitro diagnostic regulation IVDr is not the end of regulatory responsibility. IVD post market surveillance support is central to maintaining compliance and protecting patients and users. We help you design and maintain post market surveillance pms systems that are proportionate to the risk class and intended purpose of your IVD devices.

A compliant pms system collects and evaluates real world data once the IVD medical device is on the market. This includes complaint handling, trend reporting, vigilance, field safety corrective actions, and periodic safety update reports where required. We support the development of pms plans that define data sources, responsibilities, reporting timelines, and escalation criteria.

For higher risk vitro diagnostic IVD products, post market performance follow up may be required. We assist in defining post market performance follow up activities, linking them back to the original performance evaluation process. This creates a continuous feedback loop between pre market evidence and real world data. We review whether clinical performance evaluates remain valid in light of post market findings and whether additional clinical performance studies are needed.

We also help integrate pms outputs into the wider quality management system. Trends identified through complaints or field data may trigger updates to risk management, labelling, or the performance evaluation report. We ensure that changes are documented, assessed for regulatory impact, and communicated to the notified body where required. This structured approach supports ongoing conformity with safety and performance requirements.

Our IVD post market surveillance support includes preparation of periodic safety update reports, summary of safety and performance documents where applicable, and support during notified body audits. We review data analysis methods, statistical trending, and justification of conclusions. The aim is to present a transparent and defensible assessment of device performance in real use conditions.

Integrated lifecycle support under IVDR

IVD performance evaluation support and IVD post market surveillance support are not separate services in practice. Under the medical devices regulation and IVDR framework, they form part of a single lifecycle approach. Evidence generated during analytical performance studies and clinical performance studies informs initial conformity assessment. Post market surveillance pms activities then confirm whether assumptions made during development remain valid.

We provide integrated support across this lifecycle. From defining the intended purpose and planning performance evaluation studies, through drafting the performance evaluation report, to analysing real world data after launch, we maintain continuity. This reduces duplication, supports internal knowledge retention, and provides a consistent narrative for your notified body.

For manufacturers of vitro diagnostic medical devices operating in the EU, UK, or other regulated markets, the regulatory environment continues to evolve. Expectations around scientific validity analytical performance and clinical performance are high. Documentation must be structured, current, and aligned with the vitro diagnostic regulation IVDr.

We work as an extension of your regulatory and quality team. Our objective is to provide practical, evidence based IVD performance evaluation support and IVD post market surveillance support that stands up to scrutiny. By focusing on data quality, traceability, and a clear benefit risk ratio, we help you maintain compliance and protect continued market access for your IVD devices.